|Moderated By: Smacs -- (Not Moderated) -- Started: 2/17/2000 6:12:00 AM Revision History|
Vasogen has been touted by analysts as one of the most promising Biotechs in Canada with 3 products currently in clinical trials and another two only months away. That will put them in a very promising position with 5 products in clinical trials at one time! With an unbelieveable roster on their Scientific Advisory Panel and extremely positive results so far in both cardiovascular and immuno products, the future looks great for Vasogen.
Corporate Profile (from their website)
Vasogen Inc. is focused on the development and commercialization of immune modulation therapies to advance the treatment of cardiovascular, autoimmune and related inflammatory diseases. These therapies utilize components derived from a sample of a patient's own blood that has been modified by physicochemical biological modifiers. Research has shown that returning modified cellular and extracellular blood components by intra-muscular injection down-regulates self-destructive immune system activity, resulting in lower levels of inflammation, less tissue damage, and a reduction in disease. The Company has immune modulation therapies in development for the treatment of cardiovascular and autoimmune disease, and for the prevention or amelioration of ischemia/reperfusion injury. Vasogen is also developing a process to prevent Graft-versus-Host Disease, a life threatening complication of bone marrow transplantation.
Delivered by a platform medical device technology, Vasogen's therapies are designed to target fundamental disease causing processes more effectively while causing fewer side effects than current therapies. In collaboration with leading university centers, the Company has an active research and development program for new products. The Company controls the development and manufacture of its technologies for use in research and development activities and continues to advance its product development program to support future commercial scale production. The Company's policy is to secure intellectual property protection on inventions, technology, and improvements that are important to the development of its business and with respect to the application of its immune modulation therapies to the treatment of a number of disease indications.
The Company intends to commercialize its immune modulation therapies by partnering with established health care companies.
Copyright © 1995-2013 Knight Sac Media. All rights reserved.